Paul Choi analyst GOLDMAN SACHS

Currently out of the existing stock ratings of Paul Choi, 37 are a SELL (20.56%), 68 are a HOLD (37.78%), 75 are a BUY (41.67%).

Paul Choi

Work Performance Price Targets & Ratings Chart

Analyst Paul Choi, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 61.12% that have a potential upside of 34.67% achieved within 139 days.

Paul Choi’s has documented 372 price targets and ratings displayed on 38 stocks. The coverage is on Healthcare, Pharmaceuticals sectors.

Most recent stock forecast was given on PTCT, PTC Therapeutics at 04-Dec-2024.

Wall Street Analyst Paul Choi

Analyst best performing recommendations are on SBTX (SILVERBACK THERAPEUTICS ).
The best stock recommendation documented was for VIR (VIR BIOTECHNOLOGY) at 3/1/2021. The price target of $61 was fulfilled within 1 day with a profit of $5.73 (8.59%) receiving and performance score of 85.87.

Average potential price target upside

ALLK Allakos AMRN Amarin PLC AXLA Axcella Health BBIO BridgeBio Pharma ESPR Esperion Therapeutics FGEN FibroGen FREQ Frequency Therapeutics HCM HUTCHMED DRC KNSA Kiniksa Pharmaceuticals Ltd MYOV Myovant Sciences Ltd NBIX Neurocrine Biosciences NKTR Nektar Therapeutics ODT Odonate Therapeutics PBYI Puma Biotechnology PHAT Phathom Pharmaceuticals PMVP Pmv Pharmaceuticals  TPTX Turning Point Therapeutics URGN UroGen Pharma Ltd VIE Viela Bio VIR Vir Biotechnology BHVN Biohaven Pharmaceutical Holding Co Ltd NGM NGM Biopharmaceuticals FHTX Foghorn Therapeutics  IMMU Immunomedics SBTX Silverback Therapeutics  CLVS Clovis Oncology SWTX SpringWorks Therapeutics XLRN Acceleron Pharma GOSS Gossamer Bio AIMT Aimmune Therapeutics GBT Global Blood Therapeutics KNTE Kinnate Biopharma  MDCO The Medicines Company MGTA Magenta Therapeutics RDUS Schnitzer Steel Industries ASND Ascendis Pharma AS PTCT PTC Therapeutics CYTK Cytokinetics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$3

$1.8 (150.00%)

$3

2 months 25 days ago
(26-Sep-2024)

0/4 (0%)

$2.42 (417.24%)

Hold

$7

6 months 1 days ago
(20-Jun-2024)

1/3 (33.33%)

$0.45 (6.87%)

57

Sell

$1

$-0.2 (-16.67%)

$1.5

11 months 4 days ago
(17-Jan-2024)

6/6 (100%)

$-0.02 (-1.96%)

278

Buy

1 years 3 days ago
(18-Dec-2023)

1/1 (100%)

$32.69 (83.16%)

358

Buy

$9

$7.8 (650.00%)

1 years 7 months 10 days ago
(11-May-2023)

2/4 (50%)

$4.84 (116.35%)

178

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Paul Choi is most bullish on?

Potential upside of $4.55 has been obtained for PHAT (PHATHOM PHARMACEUTICALS)

Which stock is Paul Choi is most reserved on?

Potential downside of -$4.24 has been obtained for PTCT (PTC THERAPEUTICS)

What Year was the first public recommendation made by Paul Choi?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?